HS
PDLI

HighVista Strategies’s PDL BioPharma, Inc. PDLI Stock Holding History

HighVista Strategies’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,700
Closed -$37K – 146
2020
Q2 		$37K Sell
12,700
-10,200
-45% -$32.3K 0.03% 99
2020
Q1 		$65K Sell
22,900
-1,000
-4% -$3.22K 0.06% 34
2019
Q4 		$78K Buy
23,900
+1,000
+4% +$2.9K 0.06% 99
2019
Q3 		$49K Buy
+22,900
New +$61.2K 0.03% 124
2017
Q2 		– Sell
-11,800
Closed -$27K – 260
2017
Q1 		$27K Buy
11,800
+500
+4% +$1.11K 0.01% 145
2016
Q4 		$24K Buy
+11,300
New +$31.5K ﹤0.01% 166

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighVista Strategies's PDLI Position: Q3 2020 in Review

HighVista Strategies sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 12,700 shares — an estimated $37K sold.

HighVista Strategies first reported a position in PDLI in Q4 2016 and held it in 6 quarters. The position peaked at $78K in Q4 2019. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • HighVista Strategies reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • HighVista Strategies sold 12,700 PDL BioPharma, Inc. shares in Q3 2020, an estimated $37K.
  • HighVista Strategies first reported a position in PDL BioPharma, Inc. in Q4 2016 and held it in 6 quarters.
  • HighVista Strategies's PDL BioPharma, Inc. position peaked at $78K in Q4 2019.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on HighVista Strategies's 13F filing for Q3 2020, filed 16 Nov 2020.